唯万密封（301161）公告，公司股东华轩基金计划自公告披露之日起十五个交易日后的三个月内，以集 中竞价方式减持公司股份95.7万股，即不超过公司总股本的0.7975%。减持期间内，公司如有派息、送 股、资本公积金转增股本、配股、股份回购注销等股份变动事项，拟减持股份数量、价格将相应进行调 整，但减持股份占公司总股本的比例不变。 ...

Group 1 - Daqian Ecology announced that shareholder Xinhua Publishing Group plans to reduce its stake by up to 4,071,600 shares, representing no more than 3% of the total share capital [2] - Vice President Wang Zheng'an intends to reduce his holdings by up to 410,798 shares, which is no more than 25% of his total holdings and approximately 0.3027% of the company's total share capital [2] - The reduction period is set from June 16, 2025, to September 15, 2025 [2] Group 2 - Sanofi's stock has experienced a significant increase, with a cumulative rise of over 30% in two consecutive trading days and over 100% in four consecutive trading days, indicating abnormal trading fluctuations [2] - The company has entered into a collaboration with Pfizer for the 707 project, which involves a dual-specific antibody product targeting PD-1 and VEGF, with uncertain sales milestone payments and royalties based on market conditions [2] - The actual receipt of sales milestone payments and royalties is subject to uncertainties related to drug demand, market competition, and sales channels [2] Group 3 - Xinhua Insurance announced a commitment to invest 10 billion yuan in the second phase of the Honghu Fund, which has a total fund size of 20 billion yuan [3] - The establishment of the fund is pending regulatory procedures, and the implementation timeline may vary [3] - Sany Heavy Industry has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange, with the application materials being subject to updates [3] Group 4 - Laisentongling's stock has seen a 33.17% increase over three consecutive trading days, with a turnover rate of 40.49%, indicating potential speculative trading [3] - The company confirmed that its main operations remain stable, with no significant changes in daily operations or major contracts signed recently [3] - The production costs and sales conditions are reported to be normal [3]

Core Viewpoint - The actual controller of Hangdian Co., Ltd. plans to reduce his shareholding due to personal financial needs, which will not impact the company's ongoing operations [1]. Financial Performance - In 2024, the company achieved a revenue of 8.85 billion, representing a year-on-year increase of 20.17% compared to 2023 [2][3]. - The net profit attributable to shareholders was 138 million, a slight increase of 1.72% year-on-year [2][3]. - The net profit after deducting non-recurring gains and losses was 101 million, showing a decrease of 9.87% year-on-year [2][3]. - The net cash flow from operating activities was 91 million, down 66.50% year-on-year [2][3]. Shareholding Reduction Plan - The actual controller, Sun Qingyan, plans to reduce his holdings by up to 13,362,259 shares, which is no more than 1% of the total shares through centralized bidding and no more than 2% through block trading [1]. - The reduction plan will be executed within three months after a 15 trading day period following the announcement [1]. - The share reduction will be adjusted if there are any stock dividends or capital reserve transfers during the reduction period [1].

银禧科技（300221）公告，公司职工代表董事谭映儿与财务总监顾险峰拟计划自公告发布之日起十五个 交易日后三个月内，通过集中竞价方式合计减持不超过51000股股份，占公司总股本0.01%。其中，谭 映儿拟减持3800股，占总股本0.0008%；顾险峰拟减持47200股，占总股本0.0098%。减持原因主要为个 人资金需求，减持价格将根据市场价格确定。 ...

深圳市路维光电股份有限公司 上市公司名称：深圳市路维光电股份有限公司 股票上市地点：上海证券交易所 股票简称：路维光电 股票代码：688401 股份变动性质：股份减持（持股比例变动至 5%以下） 签署日期：2025 年 5 月 19 日 信息披露义务人声明 一、本报告书系根据《中华人民共和国证券法》《上市公司收购管理办法》 《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》 及其他相关法律法规编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人合伙协议或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》的规定，本 报告书已全面披露了信息披露义务人在深圳市路维光电股份有限公司（以下简称 "路维光电"、"公司"、"上市公司"）中拥有权益的股份变动情况。 信息披露义务人一：深圳市兴森快捷电路科技股份有限公司 住所：深圳市南山区粤海街道沙河西路与白石路交汇处深圳湾科技生态园一区 2 栋 A 座 8-9 层 通讯地址：深圳市南山区粤海街道 ...

Group 1 - The controlling shareholder, Inner Mongolia Jinhai Holdings Co., Ltd., plans to reduce its stake in Jinhai Biological by up to 22,563,389 shares, representing no more than 3% of the total share capital [1] - The reduction will occur within three months from June 10, 2025, to September 9, 2025, through centralized bidding and block trading [1] - The reason for the share reduction is to repay pledged debts, with shares originating from a previous restructuring and capital increases [1] Group 2 - In a previous non-public offering on August 10, 2021, Jinhai Biological issued 145,132,743 shares at a price of 5.65 yuan per share, raising approximately 820 million yuan [2] - After deducting issuance costs, the net funds raised amounted to approximately 802 million yuan, with 145 million yuan allocated to share capital and over 657 million yuan to capital reserves [2]

Core Viewpoint - The announcement reveals plans for significant share reductions by major shareholders and executives of Mingyue Lens, indicating potential changes in ownership dynamics and investor sentiment towards the company [1][2][3] Group 1: Shareholder Reductions - The controlling shareholder, Shanghai Mingyue Industrial Co., Ltd., and its actual controllers plan to reduce their holdings by up to 6,000,000 shares, representing 2.9891% of the total share capital excluding repurchased shares, within a three-month period from June 11 to September 10, 2025 [1] - The board member and deputy general manager, Zeng Zhe, intends to reduce his holdings by up to 800,000 shares, which is 24.4312% of his total shares, equating to 0.3985% of the total share capital excluding repurchased shares [2] - Shareholder Nuo Wei Qi plans to reduce his holdings by up to 3,000,000 shares, representing 1.4945% of the total share capital excluding repurchased shares [2] Group 2: Shareholder Relationships - The actual controllers, Xie Gongwan, Xie Gongxing, and Zeng Shaohua, are related, with Xie Gongwan and Xie Gongxing being brothers and Zeng Shaohua being Xie Gongwan's sister's spouse; they collectively hold 100% of Shanghai Mingyue [3] - The relationship among the shareholders indicates a coordinated approach to share reduction, as they are considered acting in concert [3] Group 3: Company Background - Mingyue Lens was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on December 16, 2021, with an initial public offering of 33.5854 million shares at a price of 26.91 yuan per share [3] - The total funds raised from the IPO amounted to 904 million yuan, with a net amount of 793 million yuan after deducting issuance costs, exceeding the original plan by 225 million yuan [3] - The funds raised are intended for various projects, including high-end resin lens expansion, conventional resin lens expansion and technology upgrades, research center construction, and marketing network development [3]

Core Viewpoint - The company, Jiejia Weichuang, announced a share reduction plan by its major shareholders, which may impact the stock price and investor sentiment in the short term [1][2]. Share Reduction Plans - Major shareholder and general manager Yu Zhong plans to reduce his holdings by up to 1,734,000 shares, representing 0.50% of the total share capital, within a three-month window starting from June 10, 2025 [1]. - Another major shareholder, Liang Meizhen, through her associate Jiang Zeyu, plans to reduce holdings by up to 968,000 shares (0.28%) via centralized bidding and up to 5,203,000 shares (1.50%) through block trading during the same period [2]. Company Background - Jiejia Weichuang was listed on the Shenzhen Stock Exchange on August 10, 2018, and primarily engages in the research, production, and sales of solar photovoltaic cell equipment [3]. - The company has raised a total of 3.633 billion yuan through two fundraising events since its IPO, with the latest fundraising amounting to 2.4999999 billion yuan in April 2021 [3][4]. Fund Utilization - The funds raised are allocated for various projects, including the construction of solar cell manufacturing production lines, smart manufacturing workshops for crystalline silicon solar cells, and the establishment of a research and testing center [3].

金河生物（002688）公告，控股股东金河控股计划在2025年6月10日至2025年9月9日期间，通过集中竞 价交易和大宗交易方式减持公司股份不超过2256.34万股，即不超过公司总股本的3%。其中，通过集中 竞价方式减持不超过752.11万股，占总股本比例1%；通过大宗交易方式减持不超过1504.23万股，占总 股本比例2%。减持原因是偿还质押债务，减持价格将根据市场价格确定。 ...

证券代码：688096 证券简称：京源环保 公告编号：2025-035 截至本公告披露日，江苏京源环保股份有限公司（以下简称"公司"）董事、 高级管理人员、核心技术人员季献华先生直接持有公司股份 4,921,001 股,通过 南通 和源投资中心（有限合 伙）间接持有公司股份 280,000 股，合计持股 有公司股份 3,005,600 股，占公司总股本的 1.812%。上述股份来源于公司首次 公开发行股票（以下简称"IPO"）前取得、公司 2021 年限制性股票激励计划归 属取得及公司资本公积金转增股本增加的股份。 ? 减持计划的主要内容 因自身资金需要，季献华先生拟通过集中竞价、大宗交易方式合计减持公司 股份数量不超过 1,200,000 股，占公司总股本的比例不超过 0.724%；苏海娟女 士拟通过集中竞价、大宗交易方式合计减持公司股份数量不超过 750,000 股，占 公司总股本的比例不超过 0.452%。上述股东减持期间为自本公告披露之日起 15 个交易日后的 3 个月内，股份减持价格按减持实施时的市场价格确定。在减持计 划实施期间，公司若发生派发红利、送红股、资本公积金转增股本、增发新股或 配股等除 ...